{"id":46478,"date":"2025-10-21T12:00:00","date_gmt":"2025-10-21T10:00:00","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/type-i-ifns-decrease-sars-cov-2-replication-in-human-cardiomyocytes-and-increase-cytokine-production-in-macrophages\/"},"modified":"2025-10-21T12:00:00","modified_gmt":"2025-10-21T10:00:00","slug":"type-i-ifns-decrease-sars-cov-2-replication-in-human-cardiomyocytes-and-increase-cytokine-production-in-macrophages","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/type-i-ifns-decrease-sars-cov-2-replication-in-human-cardiomyocytes-and-increase-cytokine-production-in-macrophages\/","title":{"rendered":"Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages"},"content":{"rendered":"<div>\n<p><b>J Clin Immunol<\/b>. 2025 Oct 21;45(1):149. doi: 10.1007\/s10875-025-01943-6.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1<sup>comp<\/sup>) and deficient (IFNAR1<sup>def<\/sup>) induced pluripotent stem cells (iPSCs), and analyzed virus replication and cytokine production after exposure to SARS-CoV-2. Cardiomyocytes expressed the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) and showed abundant SARS-CoV-2 replication, which was higher in IFNAR1<sup>def<\/sup> than IFNAR1<sup>comp<\/sup> cells. Treatment with exogenous IFN\u03b1 mitigated infection in IFNAR1<sup>comp<\/sup>, but not in IFNAR1<sup>def<\/sup> cardiomyocytes. In contrast, macrophages did not express ACE2 and did not support SARS-CoV-2 replication, but produced pro-inflammatory cytokines upon virus exposure, which was impaired in IFNAR1<sup>def<\/sup> macrophages. In conclusion, type I IFNs decrease SARS-CoV-2 replication in human iPSC-derived cardiomyocytes, while they increase cytokine responses of macrophages.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41117873\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=8102137&amp;ff=20251022114903&amp;v=2.18.0.post22+67771e2\">41117873<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1007\/s10875-025-01943-6\">10.1007\/s10875-025-01943-6<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Clin Immunol. 2025 Oct 21;45(1):149. doi: 10.1007\/s10875-025-01943-6. ABSTRACT The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1comp) and deficient (IFNAR1def) induced pluripotent stem cells (iPSCs), and analyzed virus replication and cytokine production after exposure &#8230; <a title=\"Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/type-i-ifns-decrease-sars-cov-2-replication-in-human-cardiomyocytes-and-increase-cytokine-production-in-macrophages\/\" aria-label=\"Read more about Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,42],"tags":[],"class_list":["post-46478","post","type-post","status-publish","format-standard","hentry","category-journal-of-clinical-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/46478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=46478"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/46478\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=46478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=46478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=46478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}